TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 338
Summary
- Conditions
- Gastroesophageal Cancer
- Cholangiocarcinoma
- Colorectal Cancer
- Hepatocellular Carcinoma
- Metastatic Castration Resistant Prostate Cancer
- Non -Small Cell Lung Cancer
- Pancreatic Cancer
- Renal Cell Carcinoma
- Sarcoma
- Squamous Cell Carcinoma of Head and Neck
- Triple -Negative Breast Cancer
- Urothelial Carcinoma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This is a phase 1/1b open label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of TPST-1120, a small molecule selective antagonist of PPAR? (peroxisome proliferator activated receptor alpha) in adu...
This is a phase 1/1b open label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of TPST-1120, a small molecule selective antagonist of PPAR? (peroxisome proliferator activated receptor alpha) in adult subjects with selected advanced solid tumors. TPST-1120 will be administered as monotherapy and in combination with a systemic anticancer agent, nivolumab, an anti-PD1 antibody, in subjects with advanced solid tumors. This trial is composed of dose escalation and dose expansion cohorts.
Tracking Information
- NCT #
- NCT03829436
- Collaborators
- Not Provided
- Investigators
- Study Director: Robert Stagg, PharmD Tempest Therapeutics
Get Well Soon